logo

中东和非洲二肽肽酶 4 (DPP-4) 抑制剂市场 - 增长、趋势、COVID-19 影响和预测（2022 - 2027 年）

市场按药物（Januvia、Onglyza/Kombiglyze、Tradjenta、Nesina、Galvus 和其他药物）和地理划分。

Home Industry Reports Healthcare 中东和非洲二肽肽酶 4 (DPP-4) 抑制剂市场 - 增长、趋势、COVID-19 影响和预测（2022 - 2027 年）

市场快照

Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: 0 %
Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

  • 2018 年中东和非洲的 DPP-4 抑制剂市场价值为 6.0690 亿美元，预计在预测期间（2019-2024 年）的复合年增长率为 5.6%。
  • 据估计，中东地区大多数国家的消费者在糖尿病方面的花费约为 170 亿美元。
  • 该地区糖尿病人口特别是2型人口增加的主要原因是不健康的生活方式，例如饮食和工作爱好。
  • 对于大多数人来说，久坐不动的生活方式和看似无穷无尽的快餐选择已经取代了传统的工作、旅行和美食方式，为 2 型糖尿病等疾病的增加让路。
  • 2 型人口的增加与该地区 DPP-4 市场的增长直接相关，因为它是一种仅由 2 型人口使用的药物。

报告范围

市场按品牌细分，涵盖以下品牌：Januvia、Onglyza/Kombiglyze、Tradjenta、Nesina、Galvus 等品牌。此外，该报告按中东和非洲地区的国家/地区划分。

By Drug
Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Geography
Middle East & Africa
Saudi Arabia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Iran (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Egypt (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Oman (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
South Africa (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Middle & Africa (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

Report scope can be customized per your requirements. Click here.

主要市场趋势

在预测期内，Tradjenta 市场可能会以 16.05% 的复合年增长率增长。

  • 预计 tradjenta 市场在预测期内的复合年增长率为 16.05%，预计将超过 2018 年占据最大市场份额的 Januvia 市场。
  • Tradjenta 市场包括其组合 Jentadueto 和 Jentadueto XR，利格列汀 (Tradjenta) 和盐酸二甲双胍的组合，用于治疗 2 型糖尿病。
  • 在预测期内，中东和非洲地区 2 型糖尿病和肥胖人口的增加可能会推动市场的增长。
  • 在中东和非洲，2型糖尿病患者人数一直在增长，复合年增长率为4.38%，2018年糖尿病患者总数达到1560万。

 

Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Key Trends

沙特阿拉伯在中东和非洲地区拥有最高的市场份额

  • 在中东和非洲地区，沙特阿拉伯的市场份额最高，2018 年收入为 2 亿美元。
  • 市场 DPP-4 与不断增长的 2 型糖尿病人口成正比。在大多数情况下，DPP-4 药物是为 2 型患者开出的二线药物。 
  • 根据以色列国防军的数据，沙特阿拉伯的支出最多，为 131 亿美元，伊朗为 86 亿美元，埃及为 79 亿美元。 
  • 此外，中东和非洲人均糖尿病支出最高的是沙特阿拉伯，为 6,602 美元。

 

Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Growth by Region

竞争格局

DPP-4 药物类别的持续发展和创新正在增加 DPP-4 的市场。

  • DPP-4 通过间接促进上皮间质转化和减少瘢痕形成来改善糖尿病患者的伤口愈合。
  • 勃林格殷格翰和礼来公司宣布了 Tradjenta 的 CARMELINA®心血管结局试验。两家公司宣布，他们从试验中获得了积极的顶线结果，该试验评估了 Tradjenta 治疗与安慰剂相比对心血管安全性的影响以及标准护理。
Merck and Co., AstraZeneca, Bristol Myers Squibb, Novartis, Takeda Pharmaceuticals, Eli Lilly, Boehringer Ingelheim

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)

        1. 5.1.1.1 Januvia (Sitagliptin)

        2. 5.1.1.2 Onglyza (Saxagliptin)

        3. 5.1.1.3 Tradjenta (Linagliptin)

        4. 5.1.1.4 Vipidia/Nesina (Alogliptin)

        5. 5.1.1.5 Galvus (Vildagliptin)

    2. 5.2 Geography

      1. 5.2.1 Middle East & Africa

        1. 5.2.1.1 Saudi Arabia (Value and Volume, 2012-2024)

          1. 5.2.1.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        2. 5.2.1.2 Iran (Value and Volume, 2012-2024)

          1. 5.2.1.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        3. 5.2.1.3 Egypt (Value and Volume, 2012-2024)

          1. 5.2.1.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        4. 5.2.1.4 Oman (Value and Volume, 2012-2024)

          1. 5.2.1.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        5. 5.2.1.5 South Africa (Value and Volume, 2012-2024)

          1. 5.2.1.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        6. 5.2.1.6 Rest of Middle & Africa (Value and Volume, 2012-2024)

          1. 5.2.1.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2012-2024)

    2. 6.2 Type-2 Diabetes Population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Merck and Co.

      2. 7.1.2 AstraZeneca

      3. 7.1.3 Bristol Myers Squibb

      4. 7.1.4 Novartis

      5. 7.1.5 Takeda Pharmaceuticals

      6. 7.1.6 Eli Lilly

      7. 7.1.7 Boehringer Ingelheim

    2. 7.2 Company Share Analysis

      1. 7.2.1 Merck and Co.

      2. 7.2.2 AstraZeneca

      3. 7.2.3 Takeda Pharmaceuticals

      4. 7.2.4 Novartis

      5. 7.2.5 Eli Lilly & Boehringer Ingelheim

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The MEA Dipeptide Peptidase 4 (DPP-4) Inhibitors Market market is studied from 2016 - 2027.

The MEA Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is growing at a CAGR of 0% over the next 5 years.

Eli Lilly, Astrazeneca, Merck, Novartis are the major companies operating in MEA Dipeptide Peptidase 4 (DPP-4) Inhibitors Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!